Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB

Park Avenue Securities LLC increased its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 5.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,940 shares of the company’s stock after buying an additional 832 shares during the quarter. Park Avenue Securities LLC’s holdings in Genmab A/S were worth $309,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Headlands Technologies LLC boosted its holdings in Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after purchasing an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after purchasing an additional 1,070 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Genmab A/S by 377.5% during the second quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock valued at $77,000 after purchasing an additional 2,941 shares in the last quarter. Brooklyn Investment Group boosted its holdings in Genmab A/S by 729.3% during the first quarter. Brooklyn Investment Group now owns 4,246 shares of the company’s stock valued at $83,000 after purchasing an additional 3,734 shares in the last quarter. Finally, Advisors Preferred LLC acquired a new stake in Genmab A/S during the first quarter valued at approximately $84,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Wall Street Zen raised Genmab A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, September 26th. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Tuesday, September 23rd. HC Wainwright increased their price target on Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, August 15th. Finally, Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $30.67 on Wednesday. The firm’s 50-day moving average is $25.29 and its 200-day moving average is $22.19. The stock has a market cap of $19.68 billion, a price-to-earnings ratio of 15.41, a PEG ratio of 1.68 and a beta of 0.93. Genmab A/S Sponsored ADR has a 52-week low of $17.24 and a 52-week high of $30.85.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. Sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.